DermWORX / LETI Laboratories To Launch Leading Atopic Skincare Line To The U.S. Market - Action News 5 - Memphis, Tennessee

DermWORX / LETI Laboratories To Launch Leading Atopic Skincare Line To The U.S. Market

Information contained on this page is provided by an independent third-party content provider. WorldNow and this Station make no warranties or representations in connection therewith. If you have any questions or comments about this page please contact pressreleases@worldnow.com.

SOURCE DermWORX Professional Skincare

Partnership Represents LETI's Inaugural Launch in North America

CHATHAM, N.J., June 17, 2014 /PRNewswire/ -- DermWORX Professional Skincare and LETI Laboratories announce plans to launch a series of top European dermatological products in the United States.  This includes LETI's leading dermatology line for atopic skin, AT4, which DermWORX will market to U.S. healthcare professionals and their patients beginning in Q3, 2014.  LETI Laboratories, a strategic founding partner for DermWORX, brings 95 years of experience in biopharmaceuticals, skincare, allergy & immunology to the collaboration. They are headquartered in Barcelona, Spain.

DermWORX and LETI Laboratories to launch leading dermatitis line in the U.S. The partnership represents LETI’s inaugural launch in North America.

"DermWORX and LETI share a passion for creating high-quality skin therapeutics and products that improve people's lives, particularity those with compromised skin," says Jaime Grego, President of LETI. "For nearly 100 years, LETI has earned the loyalty of physicians and their patients with safe and effective solutions like AT4.  We are thrilled to make these products available in the United States through our partnership with DermWORX."  

Allergic skin disease is a growing worldwide epidemic, with more than one in five people experiencing symptoms at some time in their lives.  DermWORX will unveil LETI's number-one selling AT4 line of products designed specifically for children and adults with atopic skin.  Widely recommended by pediatricians and dermatologists in Europe and South America, the AT4 line provides gentle, daily care that integrates seamlessly with treatment plans provided by medical professionals.  

"DermWORX is fortunate to have LETI as a strategic partner, as it provides us the opportunity to introduce proven, effective and successful products into the U.S. market for patients who very much need them.  Atopic skin is different from normal skin and requires specialized care - from cleansers to moisturizers. AT4 fills this need in a meaningful way," says Tom Ford, Chief Executive Officer of DermWORX. "We've seen how these LETI products have changed patients' lives in the international market, and it is very exciting to introduce them to our customers in the U.S. medical community.  And this is only the beginning. Beyond allergic skin, LETI has a deep portfolio of established skincare solutions that are poised to really make a difference here in the U.S."

DermWORX Professional Skincare products currently include: CerumWORX™, a topical Vitamin C-based antioxidant in single-use capsules, MoistureWORX™, a spray-on & non-greasy white petrolatum moisturizer, AcneWORX™, an effective and gently hydrating acne medication and LidoWORX™, a rapid-acting topical analgesic.

In addition to the introduction of the LETI atopic line, future plans include introducing additional LETI lines in the U.S. and potential expansion of DermWORX products internationally.  LETI became a DermWORX partner and stakeholder in early 2013.

About DermWORX
DermWORX Professional Skincare is part of Juventio, LLC, a New Jersey based company, which focuses on bringing high-quality, non-prescription health products to clinicians and their patients. DermWORX brings a wide range of passions and experience to their product offerings, including scientific research, health education and advocacy, pharmaceuticals and manufacturing. For more information about DermWORX, visit www.DermWORX.com or www.facebook.com/DermWORX

About LETI Laboratories
Founded in 1919, LETI is an independent, family-owned, research-based biopharmaceutical company.  Headquartered in Barcelona, Spain, and with a research and manufacturing facility outside of Madrid, LETI is focused on Allergy, Dermatology, Vaccines, and highly specialized Diagnostics.  Besides its presence in the U.S. through Juventio LLC, LETI has subsidiaries in Germany and Portugal, as well as an international distributor network.  For more information, please visit www.leti.com/en.

Photo - http://photos.prnewswire.com/prnh/20140617/118996

©2012 PR Newswire. All Rights Reserved.

Powered by WorldNow